I gave a presentation on Understanding how researchers and practitioners use STM information at the Association of Subscription Agents annual conference The 3 Rs: Reach, Readership and Revenues last month. The (over-long!) subtitle was How data analytics and field research are transforming our understanding of researcher and practitioner use of STM information, but more specifically [read more]
The Hub is a destination site for researchers to share their views and build a dynamic, interactive community.Currently, the PLoS Hub for Clinical Trials features articles originally published in PLoS Clinical Trials, along with clinical trials articles from PLoS ONE.In the future, this new resource will expand to include articles from all the PLoS titles that publish clinical trials…. More details in the PLos FAQ at Questions about the PLoS HubsAt present, the Hub is little more than a filtered view of articles from PLoS Clinical Trials and PLoS ONE (which PLoS Clinical Trial is being merged into).
It will be worth keeping an eye on Elsevier’s newly launched OncologySTAT, which provides advertising-supported free access for registered users to over 100 Elsevier oncology journals (press release).The site will provide a lot of information. OncologySTAT integrates a multitude of authoritative professional cancer information sources, such as peer-reviewed research, news and regulatory updates, a professional drug monograph and interactions database, chemotherapy regimens, and conference coverage into one easy-to-use online destination.
Topic PagesMechanisms of immune tolerance to allergensSerine ProteasesIt takes a bit of imagination to envisage how useful these pages could be when presented with such a bare-bones attempt.Perhaps it’s unfair, but I couldn’t help comparing these Topic Pages with the Nature Publishing Group’s Reports, which also offer an aggregation of information on particular topics (albeit aimed at a broader audience, with a mix of news and science), e.g.: Nature Reports Stem CellsNature Reports Climate ChangeIt seems unlike Elsevier to show publicly such an unfinished product – compare for example the extensive global testing and refinement programme that preceded the Scopus launch. In fairness, Elsevier clearly intend to develop the products before the official launch and to offer considerably expanded functionality, including (it sounds like) social features:At the official Topic Page launch later this year, the functionality of the Topic Pages will allow scientists and researchers to alter the content and provide feedback, allowing each topic to be shaped by the suggestions made by the research community.
Both Google and Google Scholar are slowly incorporating an increasing amount of this content, and these data will be appearing in search results for Google and Google Scholar.This will make Google Scholar significantly more useful as a research tool.In his comment on the move, Peter Suber said:This is notable for a wide range of reasons…. In contrast to the various European newspaper publisher-related lawsuits, Elsevier has clearly felt that…their ability to execute business strategy is unimpeded by encouraging greater content exposure….But this misses the point that the only part of the content that Google will reveal via its search engine is the part that is already publicly available – in most cases, the article’s abstract and bibliographic record, while the full article content will remain behind the same access controls as before.
From the Guardian’s Saturday story:Anti-arms trade campaigners and writers at Reed Elsevier’s scientific journals last night welcomed the publisher’s decision to stop organising defence shows.Reed said yesterday it would sever its ties with arms fairs, bowing to pressure which included complaints from customers, shareholders and academics writing for its titles…. At the time neither of us had heard the news, and my contact said that they were under pressure from within the society membership not to place the contract with Elsevier because of this defence industry link.
From the press release:Elsevier, a leading publisher of scientific, technical and medical (STM) information, has announced that more than 900 leading research libraries and corporations from all over the world are participating in the trial of eBooks on ScienceDirect…. Following the launch, approximately 50 newly published titles will be added to the eBooks list on ScienceDirect each month, offering researchers unparalleled integration and linking between the latest online book and journal information.
Underlying operating margins are improving with good revenue growth and further cost efficiency.The market marked Elsevier’s share price down ~4% in response to the Harcourt news:“Shares in Reed Elsevier, the publishing group, fell on Thursday after it warned that revenues would be ”broadly flat“ at its US-based Harcourt Education subsidiary…. The one billionth article download has also been counted by industry-standard measurements as Elsevier is fully COUNTER compliant”Elsevier to expand eBooks programmeIWR reported a couple of days ago that “Elsevier plans to launch 4,000 scientific and technical books online next year, a major expansion to the resources already available on STM database ScienceDirect .”The expanded programme will include ebook titles published since 1995, with approximately 50 titles added to the ebooks list on ScienceDirect each month.